Longitude Capital
Growth equityMenlo Park · Series A–Late Stage · 78 people tracked
Also known as LONGITUDE CAPITAL MANAGEMENT CO., LLC · Longitude Venture Partners
Find your way into Longitude Capital
598 people in our graph share verified history with the Longitude Capital team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Invests in mid- to commercial-stage biotech and medtech with clinically de-risked assets, using spin-outs, recapitalizations, PIPEs and other structured transactions, and sources deals via its academic research network.
Source: firm website, verified Sep 15, 2026.
Team · 78 people
from the firm's website & curated & public directories
What they invest in
from 92 of 107 portfolio companiesBiotech ×60Healthtech ×58Medical Devices ×38Digital Health ×23Hardware ×8AI & Machine Learning ×7SaaS ×6Deep Tech ×3
HQs:United States×68Canada×1Switzerland×1Ireland×1Netherlands×1
Who they back
founder profiles across 40 portfolio companiesFounding team size:solo founder×232 founders×133 founders×24+ founders×2
Where their founders studiedfrom 32 founders with education data
Harvard Medical School ×4Harvard University ×2The Tuck School of Business at Dartmouth ×2UC Santa Barbara ×2University of New Hampshire ×2University of Wisconsin-Madison ×2
What their founders studiedfrom 28 founders with field-of-study data
Business & Management ×8Life Sciences ×7Medicine ×6Engineering ×4Chemistry ×3Computer Science ×3Finance & Accounting ×2
Where their founders worked beforefrom 34 founders with career history
AnaptysBio ×2Evolve Biosystems ×2Harvard Medical School ×2Johnson & Johnson ×2Kleiner Perkins ×2McKinsey & Company ×2
12 founders hold a PhD · 7 hold an MBA (of 31 with degree data)
Investments · 107 tracked
founders shown can be your intro pathBy year:2026 · 22025 · 22024 · 72023 · 22022 · 32021 · 42020 · 32019 · 32018 · 22017 · 52015 · 32014 · 339 dated
Veradermics is developing VDPHL01, an extended-release oral minoxidil tablet intended as a non-hormonal prescription treatment for pattern hair loss in women and men.
BiotechHealthtechWest Hartford, US
Reid Waldman(Chief Executive Officer and Board Member)inTim Durso(Chief Technical Officer)inDominic Carrano(Chief Financial Officer and Treasurer)inMark Neumann(Chief Commercial and Strategy Officer)John W. Childs(Director)Jane Grant-Kels(Director)
Co-investorsConnecticut InnovationsOUP (Osage University Partners)SR One Capital Managementabrdn plcInvusLifeSci Venture Partners
Ceribell is a medical technology company that develops products for detecting and monitoring seizures, including EEG-based diagnostic systems.
AI & Machine LearningDigital HealthHealthtechMedical DevicesSunnyvale, US
Josef Parvizi(Director)inXingjuan (Jane) Chao(President, CEO, Co-Founder & Director)inScott Blumberg(Executive Officer)inJoseph Taylor(Director)Raymond Woo(Executive Officer)David Stoffel(Executive Officer)
Board seatJuliet Tammenoms Bakker· per SEC Form D
Co-investorsRA CapitalRed Tree VentureShangBay Capital LLCThe Rise Fund
AEON Biopharma develops botulinum toxin biosimilars and therapeutic neurotoxin treatments for patients with neuromuscular disorders.
BiotechHealthtechMedical Devices
Robert Bancroft(President, Chief Executive Officer and Director)John Bencich(Chief Financial Officer)inChad Oh(Chief Medical Officer)inAlex Wilson(Chief Legal & Strategy Officer; Corporate Secretary)inJennifer Sy(Chief Accounting Officer)in
BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases.
BiotechHealthtechLongevityRichmond, US
Kristen Fortney, PhD(Co-Founder, CEO)Eric Morgen, MD(Co-Founder, COO)Kristen Fortney(Executive Officer, Director)inEric Morgen(Director)inDov Goldstein(Executive Officer)in
BoardPatrick Enright(Director)in
Co-investorsAndreessen HorowitzElad GilFelicis VenturesIA Seed VenturesOrbiMedPear VC+5 more
Boston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.
HealthtechMedical Devices
John AbeleinPeter NicholasLance BatesinJonathan R. Monson(Executive Vice President and Chief Financial Officer)Miriam O'Sullivan(Senior Vice President, Chief Human Resources Officer)inMichael F. Mahoney(Chairman of the Board, President and Chief Executive Officer)
Co-investorsAndera PartnersCatalyst Health VenturesCouncilExcelestar VenturesGood Growth CapitalNew Enterprise Associates (NEA)+6 more
CG Oncology develops an investigational oncolytic immunotherapy for urologic cancer patients, specifically targeting BCG-unresponsive non-muscle invasive bladder cancer.
BiotechHealthtechMedical Devices
Arthur Kuan(Chairman and Chief Executive Officer)in
Co-investorsDecheng CapitalForesite CapitalPalm Drive CapitalRA CapitalTCG CrossoverACORN BIOVENTURES+2 more
Collegium Pharmaceutical is a biopharmaceutical company developing a portfolio of medications to treat serious medical conditions.
BiotechCanton, US
Michael Heffernan(Executive Officer, Director)inPaul Brannelly(Executive Officer)inVikram Karnani(President and Chief Executive Officer, and Director)in
BoardEran Nadav(Director)John Freund(Director)Patrick Heron(Director)in
Co-investorsAPERTURE Venture PartnersEcoR1 CapitalFrazier Life SciencesBoston Millennia PartnersRA Capital
Corcept develops cortisol modulators — molecules that regulate cortisol activity at the glucocorticoid receptor — to treat serious diseases across endocrinology, oncology, metabolism, and neurology.
AI & Machine LearningBiotechHealthtechMedical Devices
Joseph K. Belanoff(Chief Executive Officer and President)
Co-investorsMountain Group Capital
CytomX is a clinical-stage biopharmaceutical company developing conditionally activated biologic cancer therapies, including antibody-based treatments designed to target tumors while limiting effects on healthy tissue.
BiotechHealthtechSouth San Francisco, US
Sean McCarthy(Executive Officer, Director)inSean A. McCarthy(Chief Executive Officer and Chairman)inMarcia P. Belvin(SVP, Chief Scientific Officer)inDawn Benson(SVP, Quality and Product Manufacturing)inWayne Chu(Chief Medical Officer)Rachael Lester(SVP, Chief Business Officer)in
Co-investorsCanaan PartnersPfizer Venture InvestmentsOrbiMedThird Rock Ventures
A biopharmaceutical company developing an artificial intelligence infrastructure platform designed for on-premises deployment in biotechnology and pharmaceutical research environments, serving biotech firms and pharma companies seeking secure access to advanced AI capabilities while retaining control over proprietary biological data; the company is also evaluating strategic alternatives for its legacy mesenchymal stem cell secretome assets after discontinuing its lead rare eye disease therapeutic program.
BiotechArlington, US
Justin Hanes(Director)inKevin Pojasek(Executive Officer)inDarius Kharabi(Executive Officer)inTodd Bazemore(Executive Officer)inMark Iwicki(Executive Officer, Director)inMary Reumuth(Executive Officer)in
Co-investorsSR One Capital ManagementYsios CapitalAtlas VentureLux CapitalRA CapitalThird Rock Ventures
Kestra Medical Technologies develops wearable medical devices and digital healthcare solutions designed for collaborative care between providers and patients.
Digital HealthHardwareHealthtechMedical Devices
Brian Webster(President, Chief Executive Officer, and Director)inTraci S. Umberger(General Counsel, Chief Administrative Officer, and Director)inVaseem Mahboob(Chief Financial Officer)inAl Ford(Chief Commercial Officer)inTimothy Moran(Chief Business Officer)
Co-investorsAndera PartnersBain Capital Life SciencesBain CapitalBain Capital Venture
Mobia Medical (formerly MicroTransponder) develops Vivistim Paired VNS Therapy, an FDA-approved treatment for stroke survivors with moderate to severe upper extremity impairment.
Digital HealthHealthtechMedical DevicesAustin, US
Richard John Foust(Executive Officer, Director)Frank McEachern(Executive Officer, Director)in
BoardNelson Bunker Curnes(Executive Officer, Director)Thomas Jordan Curnes II(Executive Officer, Director)Casey Tansey(Director)Dana Mead(Director)
Co-investorsUT Horizon FundGreen Park & Golf VenturesUS Venture Partners
RxSight develops the Light Adjustable Lens (LAL), an FDA-approved intraocular lens that surgeons can adjust after cataract surgery to fine-tune a patient's prescription once the eye has healed.
HealthtechMedical DevicesPasadena, US
Robert H. Grubbs(Director)Daniel M. Schwartz(Director)D. Verne Sharma(Executive Officer, Director)Richard Drinkward(Executive Officer)inRon Kurtz(President, Chief Executive Officer & Director)Mark Wilterding(Chief Financial Officer)in
Co-investorsFlying L PartnersForesite CapitalH.I.G. CapitalH.I.G. HealthBridge PartnersRA CapitalVisionary Ventures+2 more
BiotechSouth San Francisco, US
Grant E. Pickering(Chief Executive Officer)Ashish Khanna(Executive Officer)Jeff Fairman(Executive Officer)
BoardTracy Saxton(Director)William Newell(Director)Kurt von Emster(Director)in
Co-investorsAbingworthCTI Life Sciences Fund L.P.Foresite CapitalFrazier Life SciencesJanus Henderson InvestorsMedicxi+4 more
Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques.
BiotechHealthtech
Grant Pickering(Founder)inGrant E. Pickering(Chief Executive Officer and Director)in
Co-investorsBioRock VenturesCTI Life Sciences Fund L.P.Foresite CapitalFrazier Life SciencesRA CapitalJanus Henderson Investors+2 more
Vera Therapeutics develops medicines targeting autoimmune-driven kidney diseases, with a focus on reducing the need for dialysis or transplant.
BiotechDigital HealthMedical DevicesSouth San Francisco, US
Marshall Fordyce(Executive Officer, Director)in
BoardBeth Seidenberg(Director)inMaha Katabi(Director)inKurt von Emster(Director)inPatrick Enright(Director)inAndrew Cheng(Director)
Co-investorsKleiner PerkinsSofinnova VenturesAbingworthSofinnova Venture Partners
Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor.
BiotechHealthtechWaltham, US
LEON O. MOULDER, JR.(Director)Lonnie Moulder(Founder, CEO & Chairman)JOSEPH FARMER(Executive Officer)HUA MU(Executive Officer, Director)in
BoardPATRICK GERALD ENRIGHT(Director)inHONGBO LU(Director)
Co-investorsDelos CapitalNew Enterprise Associates (NEA)Norwest Venture PartnersQuan CapitalSR One Capital ManagementVivo Capital+1 more
Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease.
AI & Machine LearningBiotechHealthtechMedical DevicesBasel, CH
Thomas Baumert(Founder)inMark Pruzanski(Chief Executive Officer)inLuigi Manenti(Chief Medical Officer)inJon Freve(Chief Financial Officer)inBryan Yoon(General Counsel and Chief Administrative Officer)inAditya Venugopal(Chief Business Officer)in
Co-investorsAvego BioScience CapitalBioMedPartnersFrazier Life SciencesJeito CapitalNovo HoldingsOrbiMed+5 more
Aviceda is a company that presents itself as backed by a range of investors, but the page provides no concrete details about its products or business area.
BiotechDigital HealthHealthtechMedical Devices
Mohamed A. Genead(Chairman & CEO)inJeffrey Nau(Chief Executive Officer)inTarek S. Hassan(Chief Development Officer)in
Co-investorsJeito CapitalOrbiMedDigitalis Ventures
CuraSen Therapeutics is a privately funded biopharmaceutical company developing treatments that selectively activate adrenergic receptors in the brain to restore noradrenergic signaling.
BiotechHealthtech
Anthony Fordin
Co-investorsAlta Partnersabrdn plcIntermediate Capital GroupJohnson & Johnson Innovation – JJDCNew Leaf Venture PartnersPappas Capital+2 more
OrsoBio develops therapies to restore energy homeostasis in patients with severe metabolic disorders, drawing on biological research including human liver organoids and insights from metabolic pathways.
BiotechDeep TechMedical DevicesMenlo Park, US
Mani Subramanian(Executive Officer, Director)inGangadhara Ganapati(Executive Officer, Director)Dr. SubramanianDr. Myers
BoardMatthew Young(Director)inSrinivas Akkaraju(Director)
Co-investorsAscenta CapitalSamsara BioCapitalF-Prime Capital
Sydnexis is a privately held biopharmaceutical company developing SYD-101, a proprietary low-dose atropine formulation in Phase 3 clinical trials to slow the progression of pediatric progressive myopia.
BiotechDigital HealthDel Mar, US
Patrick Johnson(Executive Officer, Promoter)inMary Jaqueline Johnson(Executive Officer)Mary Jacqueline Johnson(Executive Officer)Kevin Johnson(Director)Greg Ostrow(Executive Officer, Director)Kenneth Widder(Executive Officer, Director)
Co-investorsRA CapitalVisionary Ventures
Venus develops non-invasive, energy-based medical aesthetic devices for body, face, skin, and hair treatments, integrating robotics, AI, and IoT technologies.
BiotechHardwareHealthtechMedical DevicesToronto, US
Domenic Serafino(Executive Officer, Director)inKirk Gunhus(Executive Officer)inRoss Portaro(Executive Officer)inAnna Georgiadis(Executive Officer)inMelissa Kang(Executive Officer)inMichael Mandarello(Executive Officer)in
Board seatJuliet Bakker· per SEC Form D
Co-investorsAPERTURE Venture PartnersEssex Woodlands Healthcare PartnersClarusHealthQuest Capital
A clinical-stage biopharmaceutical company developing investigational therapies for patients with liver and cardiometabolic diseases, with a lead candidate (pegozafermin) being evaluated for metabolic dysfunction-associated steatohepatitis and severe hypertriglyceridemia.
BiotechHealthtechMedical DevicesSan Francisco, US
Rohan Palekar(Founder)in
Co-investorsK2 HealthVentures
Akebia Therapeutics develops FDA-approved drug therapies for the treatment of kidney disease.
BiotechHealthtechMedical DevicesCambridge, US
John P. Butler(President and Chief Executive Officer)in
Co-investorsCincyTech
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)
Co-investorsAndreessen HorowitzAscenta CapitalDelos CapitalGeneral CatalystLightspeed Venture PartnersLumira Ventures+9 more
.png)
Amarin Corporation is a cardiovascular health pharmaceutical company developing treatments to prevent cardiovascular disease.
BiotechHealthtechMedical Devices
Co-investorsAvoro Capital AdvisorsFountain Healthcare PartnersSignet Healthcare PartnersSofinnova Ventures
Amphora provides logistics services aimed at supporting business growth and operational efficiency.
E-commerceLogistics & Supply ChainSaaS
Joan Tresserras(Founder)inAdrià Cortés(Founder)in
Co-investorsBStartupBaird CapitalF-Prime CapitalHBM Healthcare Investments
BiotechEvanston, US
Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Ashish Khanna(Secretary & Chief Business Officer)Norbert G. Riedel(Chief Executive Officer)
BoardLiam Ratcliffe(Director)Terry P. Gould(Director)
Co-investorsBain Capital Life SciencesFrazier Life SciencesLatterell Venture PartnersOUP (Osage University Partners)Agent CapitalHBM Healthcare Investments+2 more
Aptus Endosystems developed endovascular devices, including the Heli-FX EndoAnchor systems, that use helical anchors to secure stent-grafts during minimally invasive aortic aneurysm repair.
HealthtechMedia & EntertainmentMedical Devices
Co-investorsUS Venture Partners
Assembly Bio is a biopharmaceutical company developing novel therapeutic candidates for viral and liver diseases, including programs targeting herpesviruses, hepatitis delta virus, hepatitis B virus, and cholestatic liver diseases.
BiotechHealthtechMedical Devices
Jason Okazaki(Chief Executive Officer & President)inWilliam Delaney, PhD(Chief Scientific Officer)Anuj Gaggar, MD, PhD(Chief Medical Officer)
Co-investorsAvoro Capital Advisors
BiotechCambridge, US
Mohamed Genead(Executive Officer, Director)inMichael Tolentino(Executive Officer, Director)inDavid Callanan(Executive Officer)inTarek Hassan(Executive Officer)inDerek Kunimoto(Executive Officer)in
BoardDavid Guyer(Director)
Co-investorsCatalio Capital Management, LPJeito CapitalAvoro Capital AdvisorsOmega Funds
Boston Scientific develops medical devices and technologies used by healthcare professionals to treat patients across a range of conditions.
HealthtechMedical Devices
Raymond Cohenin
Co-investorsAdvent Life SciencesAndera Partners
Non-surgical, non-pharmacologic devices to induce weight loss
Co-investorsDelos CapitalArboretum VenturesHighland Capital PartnersSante Ventures
cAMPfield is a clinical-stage biopharmaceutical company developing prifemilast, a once-daily oral PDE4B-selective inhibitor for immune-mediated inflammatory diseases, primarily inflammatory bowel disease (ulcerative colitis and Crohn's disease).
BiotechHealthtech
Graham Heap(President, Research and Development)inEzequiel Neimark(Head of Clinical Development)inTaylor Spector(Head of Medical Affairs)inScott Stirn(Head of CMC)in
Co-investorsFrazier Life Sciences
BiotechChelsea, US
RICHARD BATYCKY(Executive Officer)GLENN BATCHELDER(Director)BRYAN STUART(Executive Officer)inMARK IWICKI(Executive Officer, Director)inMARTIN FREED(Executive Officer)in
BoardROB HOPFNER(Director)in
Co-investorsCanaan PartnersSofinnova VenturesBay City CapitalOrbiMedRA Capital
Cohere Health provides a platform aimed at aligning the interests of patients, physicians, and health plans to support care decisions and improve member outcomes.
AI & Machine LearningDigital HealthEnterprise SoftwareHealthtechSaaSBoston, US
Siva Namasivayam(Executive Officer, Director)inRobert Shepardson(Executive Officer)inKristen Carucci(Executive Officer)inDuncan Reese(Executive Officer)
BoardDavid Barrett(Director)Amir Debourou(Director)
Co-investorsCota CapitalFlare Capital PartnersDeerfield Management CompanyDefine VenturesFlare Capital StrategiesPolaris Partners+1 more
Cortica provides in-home, in-clinic, and telehealth neurological therapies for children with autism and developmental differences, integrating neurological, biomedical, behavioral, speech-language, and sensorimotor treatments.
Digital HealthHealthtechMedical DevicesSan Diego, US
Dr. Suzanne Goh(Founder)Neil Hattangadi(Executive Officer, Director)inBriana Elvaiah(Executive Officer)in
BoardRyan Drant(Director)inStephen Anastos(Director)Justin Brock(Director)in
Co-investors.406 VenturesAIFAPERTURE Venture PartnersCVS Health VenturesEcho Health VenturesOptum Ventures+5 more
JAN46 is an online gaming platform offering game top-ups (in-game credits/items) with automated delivery, along with esports tournaments featuring live brackets and streaming, and player community tools.
ConsumerGaming
Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.
BiotechDigital HealthHealthtechMedical DevicesFoster City, US
Lou Lange(Founder)Michael L. Riordan(Founder)inDaniel O'Dayin
Co-investorsAisling CapitalAsset Management CompanyFrazier Life SciencesKleiner PerkinsLumira VenturesMenlo Ventures+5 more
Eargo was a hearing aid company that provided high-quality hearing aids and related care services.
HealthtechMedical DevicesMountain View, US
Raphael Michel(Executive Officer, Director)Christian Gormsen(Executive Officer, Director)William Brownie(Executive Officer)Peter Tuxen Bisgaard(Director)
BoardDavid Wu(Director)inJosh Makower(Director)
Co-investorsBirchmere VenturesMaveronNew Enterprise Associates (NEA)Dolby Family VenturesMontage VenturesPatient Square Capital+1 more
Endeavor BioMedicines is a biopharmaceutical company developing medicines aimed at treating patients with serious, intractable diseases, with the goal of altering disease progression rather than only slowing it.
BiotechSan Diego, US
John Hood(Co-Founder, Chief Executive Officer & Executive Chairman)inWing Cheong Lam(Director)Bernard Davitian(Director)Raghu Saripalli(Executive Officer)Monal Mehta(Director)inMiguel de los Rios(Co-Founder & Chief Scientific Officer)in
Co-investorsFidelity InvestmentsOmega Funds
Endogenex is a clinical-stage medical device company developing the pulsENDO system, which applies non-thermal pulsed electric field to reset the body's metabolic signaling and improve function in people with type 2 diabetes.
Digital HealthHealthtechMedical DevicesMinneapolis, US
Stacey Pugh(Leadership (CEO))inChris Sorli, MD, PhD(Chief Medical Officer)inKrissy Wright(Chief Financial Officer)inLian Cunningham, MD, PhD(VP Clinical Affairs)inMelanie Hess(Regulatory Affairs Leadership)inMatt Cambronne(Technical/Engineering Leadership)in
Co-investorsArboretum VenturesIntuitive VenturesLumira Ventures
Epirium Bio develops novel oral therapeutics targeting mitochondrial dysfunction and muscle diseases, particularly muscular dystrophy.
BiotechMedical DevicesSan Diego, US
Pam Taub(M.D., FACC, Founder)Alan Maisel(M.D., Founder)Francisco Villarreal(M.D., Ph.D., Founder)Jonathan Taub(Co-founder and first Chief Executive Officer)Guillermo Ceballos(M.D., Founding Scientist)Pam Taub, M.D., FACC(Co-founder)
Co-investorsBluebird VenturesBroadview VenturesAdams Street PartnersARCH Venture PartnersVertex VenturesVertex Ventures HC
BiotechAnn Arbor, US
Antonio M. Gotto, Jr.(Director)Tim M. Mayleben(Executive Officer, Director)Gilbert S. Omenn(Director)Daniel Janney(Director)Dov A. Goldstein(Director)Roger S. Newton(Director)
Co-investorsAisling CapitalAlta PartnersArboretum VenturesARCHIMED JapanAsset Management CompanyCanaan Partners+2 more
FIRE1 develops NORM, an implantable sensor placed in the inferior vena cava to directly measure fluid volume in heart failure patients, paired with a self-management platform to help patients engage with their own care.
Digital HealthHardwareMedical DevicesDublin, IE
Co-investorsAndera PartnersLightstone VenturesNew Enterprise Associates (NEA)Gilde HealthcareGimvIreland Strategic Investment Fund+5 more
Helicore Bio develops long-acting antibody-peptide conjugate therapies for obesity and cardiometabolic disease, using proprietary GLP-1R agonist and amylin receptor agonist peptide libraries combined with a GIP ligand-binding antibody backbone.
BiotechHealthtechSouthbury, US
Kevin Russ(Chief Executive Officer)inWaters Kellogg(Director)Lucas B. Turner(Director)Joshua Dotson(Director)Holger Koehler(Director)Charles Bridge(Director)
Co-investorsOrbiMedVersant VenturesWellington Management
Predictive Oncology (POAI) operates an AI/ML platform powered by a biobank of over 150,000 tumor samples across 137 cancer types to predict tumor-drug response for oncology drug discovery.
AI & Machine LearningBiotechHealthtechPittsburgh, US
GERALD J. VARDZEL JR.(Executive Officer, Director)DOUGLAS ARMSTRONG(Executive Officer, Director)
BoardROBERT D. KEYSER JR.(Director)RICHARD AULICINO(Director)
Infinant Health develops probiotic products based on B. infantis strains that work with breast milk to support the infant gut microbiome, including its INF108 drug strain aimed at preventing necrotizing enterocolitis (NEC) in premature infants.
BiotechDigital HealthFemTechHealthtechWellness & FitnessSacramento, US
J. Bruce German(Co-founder)David Mills(Co-founder)inCarlito Lebrilla(Co-founder)Daniela Barile(Co-founder)Samara Freeman(Co-founder & Director of Intellectual Property and Regulatory Affairs)inMichael Johnson(Executive Officer, Director)
Co-investorsAcre Venture PartnersBow CapitalHorizons VenturesiSelect FundBill & Melinda Gates FoundationSpruce Capital Partners
BiotechBoston, US
Axel Bolte(Executive Officer, Director)inReinaldo Diaz(Director)Joseph Schlessinger(Executive Officer, Director)
BoardEdward Mathers(Director)Rob Hopfner(Director)inMartin Edwards(Director)
Co-investorsNew Enterprise Associates (NEA)Sanofi VenturesSofinnova VenturesPivotal Life Sciences
IntelyCare operates a healthcare talent marketplace that connects nurses with care settings including hospitals, clinics, and other healthcare facilities.
B2B MarketplacesFuture of WorkHealthtechHR TechQuincy, US
Ike Nnah(Executive Officer, Director)inDavid Coppins(Executive Officer, Director)inPrince Nnah(Director)
Co-investorsEastward Capital PartnersEndeavour VisionEquitage Ventures, L.L.C.Generator VenturesKaiser Permanente VenturesTRANSFORMATION CAPITAL+3 more
Jazz Pharmaceuticals is a biopharmaceutical company developing treatments for rare diseases and cancers, with a focus on oncology and biomarker-driven therapies such as those targeting HER2-expressing cancers.
BiotechHealthtech
Co-investorsProspect Venture PartnersRex Health VenturesSolas BioVentures
Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.
Biotech
David King(Co-Founder & CSO)inMaria Fardis(CEO)inCadmus C. Rich(Chief Medical Officer)inElaine Stracker(General Counsel)in
Co-investorsAlta PartnersCatalio Capital Management, LPDC Investment PartnersLongwood FundBiotechnology Value FundCatalio Capital Management+2 more
Lexeo is a clinical-stage genetic medicine company developing gene therapies that target the genetic causes of cardiovascular diseases.
BiotechDigital HealthHealthtechNew York City, US
Ronald Crystal, MD(Founder & Chief Scientific Adviser)R. Nolan Townsend(Chief Executive Officer)inNarinder Bhalla, MD(Chief Medical Officer)José Manuel Otero, PhD(Chief Operating Officer)Louis Tamayo(Chief Financial Officer)in
Co-investorsOrbiMed
LimFlow develops a medical device system for the treatment of chronic limb-threatening ischemia.
HealthtechMedical Devices
Co-investorsSofinnova Partners
Locus Biosciences develops engineered bacteriophage therapies for treating bacterial infections and conditions in immunology, oncology, and CNS disorders.
AI & Machine LearningBiotechDeep TechHealthtechRaleigh, US
Paul Garofolo(CEO & Co-founder)NICK TAYLOR(Executive Officer)inNick Conley(Vice President of Technology (Co-founder of EpiBiome, acquired by Locus))in
BoardGEOFFREY GLASS(Director)inDAVID JOHNSTON(Director)BARY BAILEY(Director)
Co-investorsArtis VenturesAbstract VenturesHemisphere Ventures LLCDomain AssociatesStarlight Ventures
Acquired by Shire in 2014 (now part of Takeda).
BiotechMedical Devices
Co-investorsFrazier Life SciencesOberland CapitalRiverVest Venture Partners
Molecular Templates, Inc. was a clinical-stage biopharmaceutical company formerly based in Austin, TX.
BiotechAustin, US
Co-investorsHitecVision Advisory ASSofinnova VenturesSolasta Ventures
Murj provides a software platform for cardiac clinics, tailoring its solution to each clinic's specific workflows and challenges.
Digital HealthHealthtechMedical DevicesSaaSSanta Cruz, US
Patrick Beaulieu(Founder)inTodd Butka(Founder)
BoardMark Bartell(Director)Reed Gaither(Co-founder)
Co-investorsTrue Ventures
Nalu Medical develops a non-integrated neurostimulation system that uses electrical impulses to interrupt pain signals for patients with intractable chronic nerve pain.
HardwareHealthtechMedical DevicesCarlsbad, US
Earl Fender(President & CEO)inLee Hartley(Executive Officer)inAllen Meacham(Executive Officer)inBick Sellers(Executive Officer)inThomas A. West(Executive Officer, Director)inJeffrey Swiecki(Executive Officer)
Co-investorsAPERTURE Venture PartnersB Capital GroupB4 CapitalDecheng CapitalEndeavour VisionRunway Growth Capital+1 more
.jpeg){kind=logo}
NOCD provides specialized treatment for obsessive-compulsive disorder through live video sessions with OCD-trained therapists and 24/7 in-app support between sessions, using exposure and response prevention (ERP) therapy.
Digital HealthHealthtechMental HealthChicago, US
LARRY TRUSKY(Executive Officer)inStephen Smith(Cofounder)in
BoardGLEN TULLMAN(Director)in
Co-investors7wire VenturesChicago VenturesCorewell Health VenturesF-Prime CapitalKaiser Permanente VenturesMeridian Street Capital+2 more
NxStage provides home dialysis products and support for people with chronic kidney disease and end-stage renal disease, including home hemodialysis and peritoneal dialysis.
Digital HealthHardwareHealthtechMedical DevicesLawrence, US
Co-investorsCross Creek Advisors
On Belay provides tools, resources, and guidance to support primary care teams in transitioning to value-based care models and strengthening their practices across the United States.
Enterprise SoftwareHealthtechSaaS
Co-investors.406 VenturesMaverick Ventures
Orbus Therapeutics is a clinical-stage biopharmaceutical company developing eflornithine (DFMO), an oral ODC inhibitor, as a cancer therapy.
BiotechHealthtechAptos, US
Jason Levin(Founder, Director and Chief Executive Officer)Robert M. Myers(Executive Officer, Director)
BoardMichael Wasserman(Director)Patrick Enright(Director)inElisha (Terry) Gould(Director)Ernest Mario(Director)
Co-investorsH.I.G. CapitalH.I.G. HealthBridge PartnersAbingworthAdams Street PartnersAgent Capital
This page is a distribution, marketing, and reseller partner directory for PRWeb, an online press release distribution service.
Marketing TechMedia & EntertainmentSaaS
Co-investorsAdvance Venture PartnersAngel Physicians FundAvestria VenturesAviv Venture CapitalBIGR VenturesBlue Venture Funds+15 more
Polares Medical is a medical device company developing a device for treating mitral valve regurgitation.
HealthtechMedical DevicesPalo Alto, US
Alex Khairkhahan(Founder)in
Co-investorsDecheng CapitalEarlybird Venture CapitalEndeavour VisionIDO Investments
Poseida Therapeutics develops cell therapy candidates and related platform technologies for healthcare applications.
BiotechHealthtechSan Diego, US
Eric Ostertag(Executive Officer, Director)Mark Gergen(Executive Officer, Director)
BoardAdrian Howd(Director)David Hirsch(Director)
Co-investorsAisling CapitalRapha Capital Management, LLCVivo Capital
Practice Fusion provides a cloud-based electronic health record (EHR) platform with integrated medical billing services and e-prescribing for independent medical practices.
Digital HealthHealthtechSaaSSan Francisco, US
Ryan Howard(Executive Officer, Director)in
BoardMark Goines(Director)Beth Seidenberg(Director)inMichael Harden(Director)Cora Tellez(Director)
Co-investorsBand of AngelsCanvas VenturesArtis VenturesDeerfield Management CompanyFelicis VenturesFounders Fund+6 more
Quanta is a biotech company developing orally bioavailable, CNS-penetrant small-molecule KRAS inhibitors targeting RAS-driven cancers such as pancreatic, colorectal, lung, and endometrial cancers.
BiotechDeep TechHealthtechSouth San Francisco, US
Cameron Pitt(Executive Officer, Director)inDerek Metzger(Executive Officer)
BoardMaha Katabi(Director)inPerry Nisen(Executive Officer, Director)inMaria Fardis(Director)inRajul Jain(Director)in
Co-investorsSofinnova VenturesVida VenturesBiotechnology Value FundFrazier Life Sciences
Rivus Pharmaceuticals develops mitochondrial-targeted therapies to treat cardiometabolic diseases.
BiotechDigital HealthHealthtechMedical DevicesCharlottesville, US
Francisco Portell(Co-founder & Vice President, Pharmaceutical Development)Allen Cunningham(Co-founder & Chief Operating Officer)inNancy Hargreaves(Executive Officer)Jayson Dallas(Executive Officer, Director)inShaharyar Khan(Co-founder & Chief Scientific Officer)in
BoardFrancesco De Rubertis(Director)in
Co-investorsMedicxiBain Capital Life SciencesRA Capital
A biopharmaceutical company that discovers, develops, and delivers medicines and vaccines, with research and development across respiratory, immunology and inflammation, oncology, HIV, and infectious diseases.
BiotechHealthtechMedical DevicesSan Francisco, US
Co-investorsCapital Midwest FundFrazier Life SciencesRA CapitalVivo CapitalOxford Finance LLC
Solta Medical develops and sells a portfolio of aesthetic skin treatment devices, including the Thermage line, used by medical and cosmetic practices to address common skin concerns such as skin tightening and contouring.
HardwareMedical DevicesWellness & Fitness
Co-investorsNew Enterprise Associates (NEA)
Somatus provides value-based, integrated kidney care and a congestive heart failure management solution for patients, providers, and health plan partners.
Digital HealthHealthtechMclean, US
Ikenna Okezie(Executive Officer, Director)inAlexander Houlday(Executive Officer)inStacey Queen-Pyndell(Executive Officer)Larry Renfro(Interim President & CEO)
BoardAnna Haghgooie(Director)Anthony Welters(Director)
Co-investorsFlare Capital PartnersOptum VenturesHealthQuest CapitalBlue Venture FundsDefy PartnersRA Capital+7 more
Theseus builds robotic situational awareness software using visual positioning for drones that operate in GPS-denied environments.
Advanced ManufacturingAI & Machine LearningDefense TechHardwareRoboticsSan Francisco, US
Ian Laffey(Founder)inSacha Lévy(Founder)in
Co-investorsY CombinatorAntlerFirst Round CapitalForesite CapitalLux CapitalNexTech Ventures+4 more
BiotechCambridge, US
William C. Shakespeare(Director)in
BoardIain Dukes(Executive Officer, Director)inMichael Rome(Director)inCarl Gordon(Director)in
Co-investorsForesite CapitalNextech InvestNexTech VenturesOrbiMedPontifax Venture CapitalRock Springs Capital+1 more
Constellation Pharmaceuticals was a Cambridge, MA clinical-stage biopharmaceutical company developing epigenetics-based cancer therapies, including BET and EZH2 inhibitors.
BiotechHealthtech
Co-investorsClal Biotechnology IndustriesExSight VenturesTachyon VenturesThe Column Group
BiotechCambridge, US
James G. McArthur(Executive Officer)Abraham N. Ceesay(Executive Officer)Christoph M. Adams(Executive Officer, Director)
BoardMette Kirstine Agger(Director)David Mott(Director)Sandip Agarwala(Director)
Co-investorsAlexandriaLundbeckfonden VenturesNew Enterprise Associates (NEA)
BiotechSouth San Francisco, US
Gerrit Klaerner(Executive Officer, Director)Melissa Miksch(Executive Officer)
BoardSandra Coufal(Director)David Bonita(Director)inKlaus Veitinger(Director)inRobert Alpern(Director)
Co-investorsAvoro Capital AdvisorsFrazier Life SciencesHercules Capital, Inc.OrbiMedWellington Management
BiotechSan Carlos, US
Surag Mantri(Executive Officer, Director)
BoardJustin Klein(Director)inMatthew Sprinkel(Director)Amir Abolfathi(Director)Varun Gupta(Director)in
Co-investorsBoutique Venture PartnersNeotribe VenturesVensana Capital
Viridian Therapeutics develops treatments for thyroid eye disease, a rare autoimmune condition affecting the eyes and orbit.
BiotechDigital HealthMedical DevicesWaltham, US
Jonathan Violin(Executive Officer, Director)in
BoardPeter Harwin(Director)Tomas Kiselak(Director)
Co-investorsBroadview VenturesMRL Ventures Fund
WelbeHealth operates a Program of All-Inclusive Care for the Elderly (PACE) that provides integrated medical and social services to seniors, including primary care, dental, vision, hearing, in-home care, transportation, and social activities.
Digital HealthHealthtechWellness & FitnessCalifornia, US
Si France, MD(Founder)inCLANCY SI FRANCE(MANAGER AND CHIEF EXECUTIVE OFFICER OF ISSUER)
BoardLIAM DONOHUE(MANAGER OF ISSUER)inADAM GROFF(MANAGER OF ISSUER)inMICHAEL ZUBKOFF(MANAGER OF ISSUER)JONATHAN LIM(MANAGER OF ISSUER)
Co-investors.406 VenturesF-Prime CapitalGeneral AtlanticTown Hall Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
AlphaeonAxonics Modulation TechnologiesAimmuneAirNexisAllergen ResearchAmphora MedicalAmunixAqueSysAvengebioCheckmate PharmaceuticalsCheckmatepharmaCydan IIDascenaGcs WebInflazomeNabrivaNeurana PharmaceuticalsOpna BioRapidmicrobioTalaris TherapeuticsTalaristxTourmaline BioVelicept Therapeutics
Exits · 26
17 IPOs · 9 acquisitions · showing 25VeradermicsNYSE: MANECeribellNASDAQ: CBLLAeonbiopharmaNYSE: AEONBioAge LabsNASDAQ: BIOABoston ScientificNYSE: BSXCG OncologyNASDAQ: CGONCollegium PharmaceuticalNASDAQ: COLLCorcept TherapeuticsNASDAQ: CORTCytomXNASDAQ: CTMXKALA BIONASDAQ: KALAKestra Medical TechnologiesNASDAQ: KMTSMicroTransponderNASDAQ: MOBIRxsightNASDAQ: RXSTSutroVaxNASDAQ: PCVXVaxcyteNASDAQ: PCVXVeratxNASDAQ: VERAZenas BiopharmaNASDAQ: ZBIOAmphora Medicalacq. by HologicAptus Endosystemsacq. by MedtronicCheckmate Pharmaceuticalsacq. by Regeneron PharmaceuticalsHelomicsacq. by Predictive OncologyLumena Pharmaceuticalsacq. by ShireNxStage Medicalacq. by Fresenius Medical CarePentec Health Celebrates 35th Anniversaryacq. by Wellspring Capital ManagementThumbnail for Constellation Pharmaceuticalsacq. by Morphosys
Portfolio news
latest coverage across their companiesCeribell · investing.com · Sep 11, 2026
Kestra Medical Technologies · es.investing.com · Sep 11, 2026
Vaxcyte · uk.investing.com · Sep 9, 2026
Viridian Therapeutics · investing.com · Sep 8, 2026
Corcept Therapeutics · investing.com · Sep 4, 2026
Veratx · manilatimes.net · Sep 1, 2026
Generate · tcbmag.com · Aug 20, 2026
Fund performance · per public LP disclosures
as of Jun 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Longitude Venture Partners IIILPs: Los Angeles City Employees' Retirement System, Maryland State Retirement and Pension System | 2016 | — | 16.8% | 1.68x | 0.96x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
IPO stake values · per SEC filings · 7
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Veradermics | 11.3% | $100.00 | Apr 2026 | $465.4M |
| CG Oncology | 6.2% | $28.00 | Dec 2024 | $130.5M |
| Veratx | 11.9% | $15.00 | Feb 2022 | $46.4M |
| Ceribell | 7.3% | $17.00 | Oct 2024 | $42.1M |
| Zenas Biopharma | 5.2% | $17.00 | Sep 2024 | $35.1M |
| KALA BIO | 8.8% | $15.00 | Jul 2017 | $30.8M |
| BioAge Labs | 3.8% | $18.00 | Sep 2024 | $23.6M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Public market activity · per SEC filings
what is this? ⓘ2 insider ownership filings (Forms 3/4/5)
at Veradermics, Inc (MANE)
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- How many investments has Longitude Capital made?
- Longitude Capital has 107 tracked investments, 26 of which have exited, including 5 dated in the last 24 months.
- What stage does Longitude Capital invest at?
- Longitude Capital invests at the Series A, Series B, Series C, Growth, Late Stage stages.
- What is Longitude Capital's typical check size?
- Longitude Capital typically writes checks of $10M – $30M.
- What sectors does Longitude Capital focus on?
- Longitude Capital focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Longitude Capital located?
- Longitude Capital is headquartered in Menlo Park, US.
- Does Longitude Capital lead rounds?
- Yes, Longitude Capital leads investment rounds.
- Who does Longitude Capital co-invest with?
- Longitude Capital most often shares deals with RA Capital, Frazier Life Sciences, New Enterprise Associates (NEA), among 162 tracked co-investors.
Co-investors · 6
Pivotal Life Sciences is an investment platform focused on funding innovative companies developing therapeutic products and technologies aimed at major unmet medical needs.
Menlo Ventures is a venture capital firm that invests in transformative, early-stage AI companies across every layer of the modern AI stack, from applications and middleware to data infrastructure and foundation models.
Vensana Capital is a venture capital and growth equity investment firm focused on partnering with entrepreneurs building breakthrough medical technology innovations to transform healthcare.
Bain Capital is a global private investment firm operating across private equity, growth and venture capital, credit, capital solutions, and real assets, with offices in North America, Europe, and Asia-Pacific. The firm invests across industries and business life cycles, from seed-stage venture investments through buyouts, and integrates sustainability commitments into its portfolio governance.
Longwood Fund is a venture capital firm that creates and invests in novel healthcare companies developing new treatments for patients, drawing on its partners' company-building and operating experience.
Firms observed investing alongside Longitude Capital, from public investor directories. Shared companies are the overlap with Longitude Capital's recorded portfolio.
Similar investors
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Khosla Ventures is a venture capital firm founded by Vinod Khosla.
EQT Life Sciences, formerly LSP (Life Sciences Partners), is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Lumira Ventures is a North American life sciences venture capital firm that partners with mission-driven entrepreneurs to build companies developing and commercializing healthcare products for patients.